NCT02519543View on ClinicalTrials.gov

Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Bipolar Disorder
Interventions
DRUG

Placebo

Placebo to be given twice daily, once with breakfast and once with supper

DRUG

Metformin

Active experimental drug to be given twice a day, 1000 mg with breakfast and 1000 mg with supper

Trial Locations (2)

15213-2593

Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, University of Pittsburgh, Pittsburgh

B3H 2E2

Nova Scotia Health Authority - Dept. of Psychiatry, Halifax

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

Cynthia Calkin

OTHER

NCT02519543 - Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder | Biotech Hunter | Biotech Hunter